114 results
8-K
EX-99.1
AEMD
Aethlon Medical Inc
12 Jan 11
Regulation FD Disclosure
12:00am
Emerging Pathogens
Advanced Agents
"The Aethlon Hemopurifier® is the
only strategy to address the
breadth of pathogens that could
be weaponized … provides a first-line countermeasure
strategy against threats not addressed by drug or vaccines
Enhanced Agents
Traditional threats that have been
8-K
EX-99.1
AEMD
Aethlon Medical Inc
10 Dec 10
Regulation FD Disclosure
12:00am
pox
Battelle
NO
“The Hemopurifier® is the only
strategy to address the breadth of
pathogens that could be weaponized
as agents of bioterror”
Ken … )
IN THE ABSENCE OF DRUG
THERAPY
5 Day HCV Treatment Studies
ONE WEEK STUDY - THREE HEMOPURIFIER®
TREATMENTS
OUR STRATEGY IS TO
COMBINE OUR
HEMOPURIFIER®
8-K
EX-99.1
AEMD
Aethlon Medical Inc
17 Mar 06
Regulation FD Disclosure
12:00am
.
Current Treatments
Antiviral drugs being stockpiled as part of a global strategy to treat Avian Flu
have no therapeutic value once the cytokine … ."
A successful global strategy against H5N1 will, at a minimum, have to rely on
therapeutics that can modulate the overproduction of cytokines. The March 2
8-K
EX-99
AEMD
Aethlon Medical Inc
1 Oct 10
Aethlon Medical Appoints Jim Frakes as Chief Financial Officer
12:00am
the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse … resistant to antiviral drug regimens.
Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable
8-K
EX-99.1
AEMD
Aethlon Medical Inc
1 Nov 10
Aethlon Medical Names Rod Kenley President
12:00am
strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism … advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented
8-K
nj6uk417cekk 5gm
9 Aug 18
Regulation FD Disclosure
10:10am
8-K
EX-99.1
5ca8w9t i6
22 Oct 10
Aethlon Medical Announces Appointment of Rod Kenley To Its Board of Directors
12:00am
8-K
EX-99.1
q0tpzmqz
30 Oct 18
Other Events
4:00pm
8-K
EX-99.1
gexd9eojo yc3345s4db
23 Feb 06
Entry into a Material Definitive Agreement
12:00am
8-K
ehw0c3uangj
6 Jul 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
6p2xorh442fnd2
13 Dec 18
Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer
8:29am
8-K
EX-99.1
dyqayv3q6oz
23 Sep 14
Regulation FD Disclosure
12:00am
8-K
ktehnpaxm
4 Oct 11
Aethlon Medical Receives Government Contract Award from DARPA
12:00am
8-K
EX-99.1
0rea7d 8fddyvxnp
17 Apr 19
Aethlon Medical Releases Shareholder Update
8:27am
8-K
EX-99.1
k5bel b50qsv
4 Oct 11
Aethlon Medical Receives Government Contract Award from DARPA
12:00am
8-K
5o0s9xl8k 5ju5wh8vs2
13 Dec 18
Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer
8:29am
8-K
cbu8b79r80jcsq5r
21 Feb 20
Departure of Directors or Certain Officers
5:05pm
8-K
9ldhtug
12 Jun 14
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
zmyaimz5h0bbz
1 Mar 11
Regulation FD Disclosure
12:00am
8-K
ynbrlmrzol8nhw5 0gbt
1 Oct 10
Aethlon Medical Appoints Jim Frakes as Chief Financial Officer
12:00am